Welcome to the Working Group on New TB Drugs Blog
TB R&D Weekly Update: High Dose Vitamin D May Enhance TB Treatment
This week we highlight a study showing promising results that providing high dose vitamin D supplements along with antibiotics could improve treatment outcomes for TB patients. The abstract and additional news coverage are included, as well as, links to other TB R&D news.
TB Set to Achieve Major Millennium Development Goal by 2015
The 2012 Millennium Development Report was just released highlighting progress made to date. Great strides have been made in HIV and TB from the year 1990 (see below). The Global Plan to Stop TB issued by the Stop TB Partnership is set within the context of the Millennium Development Goals (MDGs).
Unified Community Action For A TB-Free Africa Kicks Off
The Africa Coalition on Tuberculosis (ACT!) kicked off activities at a week-long planning meeting in June in Tirano, Italy. ACT!’s mission is to value and consolidate the power within communities throughout Africa to end the injustice of TB, a curable disease from which millions of our people suffer and die each year. Albert Makone, Community Representative for the Working Group on New TB Drugs, is a member of ACT!.
TB R&D Weekly Update: Results from First Novel Regimen Trial Published
Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Link to article, press release, and related video are included. Additional links to TB R&D news are also included.
TB R&D Weekly Update: Janssen Seeks Approval from FDA for Bedaquiline
This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207).
Posted in Announcements, TB Diagnostics, TB News, TB Prevention and Control Strategies
Breaking news from the Stop TB Partnership
The Stop TB Partnership made two exciting announcements today: 1. US$ 40 million committed to roll-out of Xpert and 2. Dramatic results from TB REACH mHealth project make case for wider implementation.
TB R&D Weekly Update: Delamanid Shows Promise against Multidrug-Resistant TB
This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.
TB R&D Weekly Update: Expanding Our Options for TB Treatment
For this week’s update, we will highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Additional links to TB R&D news are included.
Watch Video from the World TB Day Congressional Briefing
A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Links to video included.
-
You are currently browsing the archives for the TB News category.
-
Toppix TB News- Detection of second-line drug resistance in mycobacterium... 24 May 2013
- Effect of Isoniazid Shortage on TB Care 24 May 2013
- Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 23 May 2013
- Impact of a Shortage of First-Line Antituberculosis Medication on... 23 May 2013
- TB, a neglected disease in Uganda 15 May 2013
